N4 Pharma assigns ex AstraZeneca senior research scientist to lead Nuvec, its lead vaccine delivery program.

N4 Pharma has recruited a former AstraZeneca senior research scientist to lead the Nuvec, its lead vaccine delivery program.

N4 Pharma said that the Directors have been developing a work plan for the its proprietary Nuvec technology, as it waits the imminent beginning of pilot human trials for its reformulation of sildenafil.

Nuvec is a nanosilica system which targets the delivery of therapeutics such as RNA, DNA, vaccines and targeted cancer therapies and is being positioned as a potential alternative delivery system to lipid nanoparticles and lipid nanosomes.

Appointment of head of Nuvec development

N4 Pharma has appointment Andrew Leishman as Head of Nuvec Development. As a former Astra Zeneca’s Senior Research Scientist, N4 Pharma expects him to brings a wealth of research and development expertise to the its lead vaccine delivery program. Leishman has worked on a variety of clinical and pre-clinical assets across respiratory, inflammation and oncology for several pharmaceutical companies, N4 Pharma noted.